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Abstract—Little is known regarding fibromyalgia syndrome 
(FMS) care among Operation Iraqi Freedom/Operation Endur-
ing Freedom/Operation New Dawn (OIF/OEF/OND) Veterans. 
Current recommendations include interdisciplinary, team-
based combined care approaches and limited opioid use. In this 
study of OIF/OEF/OND Veterans who accessed Veterans 
Health Administration services between 2002 and 2012, we 
hypothesized that combined care (defined as at least 4 primary 
care visits/yr with visits to mental health and/or rheumatology) 
versus <4 primary care visits/yr only would be associated with 
lower risk of at least 2 opioid prescriptions 12 mo following an 
FMS diagnosis. Using generalized linear models with a log-
link, the Poisson family, and robust standard errors, we esti-
mated risk ratios (RRs) and 95% confidence intervals (CIs). 
We found that 1% of Veterans had at least 2 FMS diagnoses 
(International Classification of Diseases-9th Revision-Clinical 
Modification code 729.1) or at least 1 FMS diagnosis by rheu-
matology. Veterans with (vs without) FMS were more likely to 
be female, older, Hispanic, and never/currently married. Com-
bined primary, mental health, and rheumatology care was asso-
ciated with at least 2 opioid prescriptions (RR [95% CI] for 
males 2.2 [1.1–4.4] and females 2.8 [0.4–18.6]). Also, com-
bined care was associated with at least 2 nonopioid pain-
related prescriptions, a practice supported by evidence-based 
clinical practice guidelines. In tandem, these results provide 
mixed evidence of benefit of combined care for FMS. Future 
studies of healthcare encounter characteristics, care coordina-
tion, and benefits for Veterans with FMS are needed.
Key words: Afghanistan, fibromyalgia syndrome, healthcare 
setting, healthcare utilization, Iraq, OIF/OEF/OND, opioid, 
primary care, PTSD, rheumatology, Veteran.
INTRODUCTION
The prevalence of fibromyalgia syndrome (FMS), a 
condition characterized primarily by widespread chronic 
musculoskeletal pain, has been estimated to range from 
Abbreviations: CI = confidence interval, DOD = Department 
of Defense, DSS = Decision Support System, FMS = fibromy-
algia syndrome, HSR&D = Health Services Research and 
Development Service, ICD-9-CM = International Classifica-
tion of Diseases-9th Revision-Clinical Modification, OIF/
OEF/OND = Operation Iraqi Freedom/Operation Enduring 
Freedom/Operation New Dawn, PTSD = posttraumatic stress 
disorder, RR = risk ratio, VA = Department of Veterans 
Affairs, VHA = Veterans Health Administration, VINCI = VA 
Informatics Computing Infrastructure.
*Address all correspondence to April F. Mohanty, MPH, 
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1.0 to 6.0 percent in the U.S. civilian population [1–2]. 
Among U.S. Department of Defense (DOD) healthcare 
beneficiaries aged <65 yr, a prevalence of 0.7 percent has 
been reported [3]. Females and older individuals are 
more likely to be diagnosed with FMS [3–5].
The prevalence and characteristics of Operation Iraqi 
Freedom/Operation Enduring Freedom/Operation New 
Dawn (OIF/OEF/OND) Veterans (both deployed and 
nondeployed) with FMS are unknown. There is also little 
research on the healthcare utilization of Veterans with 
FMS and possible variations in treatment across different 
healthcare providers and clinics within the Veterans 
Health Administration (VHA).
Generally, evidence-based practice guidelines rec-
ommend patient-tailored approaches that may include 
several nonpharmacologic and pharmacologic strategies 
to reduce symptoms and improve functionality [6–9]. 
Briefly, nonpharmacologic strategies include patient edu-
cation, graded exercise, cognitive behavioral therapy, and 
complementary and alternative medicine therapies. Phar-
macologic strategies include treatment with serotonin 
norepinephrine reuptake inhibitors, treatment with other 
nonopioid pain-related medications, and limited treat-
ment with opioids. Guidelines also recommend interdis-
ciplinary and integrative team-based approaches that 
include regular primary care visits and possible coman-
agement with mental health and rheumatology specialists 
[6–11]. Whether interdisciplinary, team-based combined 
care approaches are associated with best practices, e.g., 
less opioid use and more use of nonopioid pain-related 
medication, is unknown.
To support the implementation of evidence-based 
management of FMS in the VHA, we examined charac-
teristics and healthcare utilization of OIF/OEF/OND Vet-
erans with FMS. Our specific objectives were to describe 
sociodemographic and military characteristics of Veter-
ans with FMS and to identify primary clinical sites of 
FMS diagnoses. Our secondary objective was to test the 
hypothesis that Veterans managed by an interdisciplinary, 
team-based approach of care for FMS (vs Veterans who 
are not) are less likely to be prescribed opioid medica-
tions and more likely to be prescribed nonopioid pain-
related medications in the 12 mo following a FMS diag-
nosis. We defined a proxy variable for an interdisciplin-
ary, team-based approach of care for FMS as combined 
utilization of regular primary care with mental health 
and/or rheumatology care within 12 mo of a diagnosis.
METHODS
Study Setting
Our cross-sectional study included Veterans from the 
national OIF/OEF/OND Roster file that is provided to the 
Department of Veterans Affairs (VA) Central Office 
Environmental Epidemiology Service by the Defense 
Manpower Data Center. The OIF/OEF/OND Roster 
includes Veterans who are a subset of military discharges 
identified as having VHA healthcare utilization. The 
OIF/OEF/OND Roster file was merged with data in the 
VA Informatics Computing Infrastructure (VINCI) [12]. 
These data include basic demographic files, clinical data, 
and all national inpatient and outpatient services pro-
vided to VHA healthcare users. Data for outpatient ser-
vices in VHA include 6-digit Decision Support System 
(DSS) identifiers. These DSS identifiers are used to char-
acterize outpatient clinic settings and are the single and 
critical designation by which VHA defines outpatient 
clinical work units for costing purposes [13]. The first 
3 digits of the DSS identifier, or primary “stop code,” 
designate the main clinical group responsible for patient 
care. The last 3 digits of the DSS identifier, or secondary 
“stop code,” can be used by a VHA medical facility to 
further specify the main clinical group, for example, to 
specify the type of service provided or type of provider/
team that administered the care. The list of nationally 
standardized codes is reviewed and updated at least annu-
ally by VHA’s National Stop Code Council, and lists of 
stop code changes and active stop codes as well as a cur-
rent stop code instructional guide are posted on the DSS 
Identifier Web page. 
Participants
The OIF/OEF/OND Roster included 647,288 male 
and 90,819 female Veterans who accessed VHA from fis-
cal years 2002–2012. Of these, we identified 15,420 male 
and 4,179 female Veterans who had ≥1 outpatient diagno-
sis of FMS by the International Classification of Diseases-
9th Revision-Clinical Modification (ICD-9-CM) code 
729.1: myalgia and myositis, unspecified. Researchers 
have cautioned that a single ICD-9-CM FMS diagnosis or 
diagnoses in nonrheumatology settings may have limited 
specificity to identify true FMS cases [1,14–15]. To 
improve the specificity of our FMS case definition and to 
be consistent with prior research of VHA administrative 
data [16], we only included Veterans who received 
≥1 FMS diagnosis in a rheumatology specialty care setting 
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(identified by corresponding clinic stop code of 314) or 
≥2 FMS diagnoses on separate dates within 12 mo, regard-
less of outpatient care setting. There were 5,963 male and 
2,245 female Veterans who met our FMS case definition.
Outpatient Settings of Index FMS Diagnoses
We defined the date of index FMS diagnosis to be the 
date of whichever came first: (1) the date of diagnosis in 
a rheumatology specialty care setting or (2) the first date 
of ≥2 FMS diagnoses (on separate dates) within 12 mo. 
We used the term “index FMS date” to distinguish our 
analysis from one that examines incident FMS, since we 
did not determine whether Veterans were free of FMS 
before the index date. In addition to rheumatology, we 
examined the top 10 primary stop codes where an FMS 
diagnosis was coded, stratified by male and female Veter-
ans, on the date of index FMS diagnosis.
Exposure Definitions: Utilization of Primary Care 
and Mental Health and Rheumatology Specialty Care
We classified primary care encounters to be any VHA 
visits with a primary stop code of 342, 348, 350, or 323, 
excluding secondary stop code 135. We classified 
encounters by mental health to be any VHA visits with a 
primary stop code of 502–524, 527–599, or 725–731. 
Rheumatology specialty care visits were classified by any 
VHA visits with a primary stop code of 314. Multiple vis-
its for categories of primary care, mental health, or rheu-
matology were counted only if they occurred on separate 
dates. Follow-up by primary care, mental health, and/or 
rheumatology was examined 12 mo after the index FMS 
date. In the absence of an explicitly stated definition of 
regular primary care in the current VA/DOD Clinical 
Practice Guideline for the Management of Chronic Multi-
symptom Illness [17], we used an empirically derived def-
inition for regular primary care as greater than or equal to 
the median number of visits over 12 mo of follow-up 
from the index date of FMS diagnosis.
Outcome Definitions: Pharmacologic Outcomes
We examined the number of uniquely dated prescrip-
tions generated for opioid and nonopioid pain-related 
medications during the 12 mo after the index FMS date. 
A complete list of opioid and nonopioid pain-related 
medications included in our analyses is in Appendix 1 
(available online only). We dichotomized users of opioid 
and nonopioid pain-related medications separately using 
a cutoff of 2 uniquely dated prescriptions in the 12 mo 
after the index FMS date.
Definitions of Potential Confounding Variables
Sociodemographic and Military Service Characteristics
We examined sociodemographic characteristics 
including age, race, marital status, and education. We 
reported age at date of first VHA encounter and age at 
index FMS date. We also examined factors related to Vet-
erans’ military service component (Active Duty vs 
reserve), rank, and branch of service.
Mental Health Comorbidities
Because mental health diagnoses of anxiety, post-
traumatic stress disorder (PTSD), and depression have 
been associated with FMS and are risk factors for opioid 
prescriptions [18], we examined these mental health 
diagnoses associated with outpatient encounters during 
the 12 mo following the index FMS date. We used ICD-
9-CM diagnostic codes 300.00–300.09, 300.20–300.29, 
and 300.3 to categorize anxiety; code 309.81 to catego-
rize PTSD; and codes 296.20–296.25, 296.30–296.36, 
300.4, and 311 to categorize depression diagnoses 
according to a previously published study of mental 
health diagnoses in the OIF/OEF/OND Veteran popula-
tion [19]. These represent a cluster of mood and anxiety 
disorders that most prior FMS research has focused on 
[20–21], but it is not an exhaustive list. Others include 
conversion and bipolar disorder, which are not the focus 
of this current study [22–23].
Charlson Comorbidity Index
The Charlson Comorbidity Index is a validated mea-
sure of the number and severity of coexisting diagnoses. 
For each Veteran with FMS, we calculated the Charlson 
Comorbidity Index [12] using ICD-9-CM diagnostic 
codes related to inpatient and outpatient encounters dur-
ing the 12 mo following the index FMS date [24].
Statistical Analysis
We examined frequency distributions of sociodemo-
graphic and military service characteristics among Veter-
ans who met our FMS case definition and Veterans who 
had no FMS diagnoses from fiscal years 2002–2012, 
stratified by sex. We used the Pearson chi-square test to 
examine statistically significant differences in the distri-
bution of these characteristics.
We examined associations between combined utiliza-
tion of regular primary care with mental health and/or 
rheumatology care as a proxy for an interdisciplinary, 
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team-based approach (vs only primary care utilization) 
and the risk of 2 opioid or 2 nonopioid pain-related 
prescriptions in the 12 mo following the index FMS diag-
nosis. We restricted our analysis to Veterans with 1 pri-
mary care visit during the 12 mo of follow-up to avoid 
including Veterans who may have sought care only out-
side of the VHA. To examine these associations, we fit 
generalized linear models with a log-link, Poisson family 
(a log-Poisson regression model), and robust standard 
errors to estimate risk ratios (RRs) and 95 percent confi-
dence intervals (CIs). The log-Poisson regression model 
with robust standard errors allows estimation of RRs for 
prospective studies with binary outcome data [25].
The following potential confounding variables were 
identified a priori and were included in all adjusted mod-
els, including Model 1: number of anxiety, PTSD, and 
depression diagnoses during the 12 mo after index FMS 
date and nonreferent indicator variables (i.e., dummy 
variables that excluded the reference category) for each 
mental health disorder (1, 2, and 3 diagnoses). We also 
adjusted for the Charlson Comorbidity Index 
(2 nonreferent indicator variables: 1 and 2). We used 
indicator variables to allow flexibility for fitting potential 
nonlinear associations. In Model 2, we additionally 
adjusted for sociodemographic and military characteristic 
variables: age at index FMS date (2 nonreferent indicator 
variables: >30–40 and >40); white, non-Hispanic race/
ethnicity; married marital status; and greater than high 
school education as well as Active Duty status and 
branch of service (4 nonreferent indicator variables: Air 
Force, Navy, Marines Corps, and Coast Guard).
There have been temporal changes in the “VA/DOD 
Clinical Practice Guideline for the Management of Opi-
oid Therapy for Chronic Pain” [26–27]. These may have 
resulted in changes to FMS management, including pre-
scribing practices of opioid and nonopioid pain-related 
medications. We explored whether our results were sensi-
tive to the adjustment for the year of index FMS diagno-
sis by including 10 nonreferent indicator variables for 
calendar years 2002–2011 [3,28]. We also explored 
whether adjustment for the index FMS setting (whether 
in a rheumatology setting) materially altered our results. 
Researchers have advised that for mental health diagno-
ses determined by ICD-9-CM codes, those who only 
have one diagnosis code may not truly have the mental 
health diagnosis [16]. To address this potential limitation, 
we also explored whether results for Model 1 were sensi-
tive to recoding of individuals who had only one ICD-9-
CM code corresponding to anxiety, PTSD, or depression 
as having no diagnosis.
All p-values were two-sided and defined to be signifi-
cant at p < 0.01. All analyses were conducted using Stata 
software (version 12.1, StataCorp; College Station, Texas).
RESULTS
Prevalence and Characteristics of Veterans with FMS
The prevalence of FMS was higher among female than 
male Veterans. There were 5,963 (0.9%) male and 2,245 
(2.5%) female Veterans, or 1 percent of male and female 
Veterans combined, with prevalent FMS according to our 
case definition among OIF/OEF/OND Veterans who had 
≥1 VHA encounter from fiscal years 2002–2012. Com-
pared with the 631,868 male and 86,640 female Veterans 
who did not have a FMS diagnosis during the 10 yr study 
period, Veterans with FMS were older, more likely to be 
Hispanic, and never or currently married, regardless of sex 
(Table 1). Females with FMS were more likely to have 
attained more than a high school education and to have 
served in the Air Force than females without FMS. Males 
with FMS were more likely to have served in the Army 
than males without FMS.
Outpatient Settings of Index FMS Diagnosis
Over a quarter of FMS diagnoses were documented 
in a primary care setting (24% for male and 29% for 
female Veterans) (Table 2). The other top five settings 
were similar for FMS diagnoses across male and female 
Veterans, including chiropractic care, physical medicine 
and rehabilitation, and rheumatology/arthritis specialty 
care settings. Eight percent of female Veterans with FMS 
received an index diagnosis in women’s health-related 
specialty clinic settings. A higher proportion of male 
(11%) versus female (6%) Veterans received their index 
FMS diagnosis in a pain specialty clinic.
Utilization of Primary Care and Mental Health and 
Rheumatology Specialty Care
Among 4,855 male and 1,786 female Veterans with 
at least 12 mo of follow-up after their FMS index date, 
most male (n = 4,441 [91%]) and female (n = 1,526 
[85%]) Veterans had ≥1 primary care encounter. Also, 
most male (n = 3,437 [71%]) and female (n = 1,299 
[73%]) Veterans had ≥1 mental health encounter. Fewer 
Characteristic
Males With FMS
(n = 5,963)
Males Without FMS
(n = 631,868)
Females With FMS
(n = 2,245)
Females Without FMS
(n = 86,640)
Age Group at First VHA Encounter (yr)*
18–30 2,734 (45.8) 343,440 (54.4)† 962 (42.9) 52,194 (60.2)†
>30–40 1,587 (26.6) 140,451 (22.2) 636 (28.3) 18,609 (21.5)
>40–50 1,295 (21.7) 115,101 (18.2) 519 (23.1) 12,677 (14.6)
>50–60 339 (5.7) 30,442 (4.8) 113 (5.0) 3,021 (3.5)
>60–75 7 (0.1) 2,262 (0.4) 6 (0.3) 136 (0.2)
Race*
White 2,915 (48.9) 362,543 (57.4)† 776 (34.6) 38,790 (44.8)†
Black 555 (9.3) 70,817 (11.2) 449 (20.0) 18,963 (21.9)
Hispanic 767 (12.9) 583 (0.1) 235 (10.5) 55 (0.1)
Other 261 (4.4) 22,595 (3.6) 166 (7.4) 3,452 (4.0)
Marital Status*
Never Married 2,427 (40.7) 199,276 (31.5)† 1,023 (45.6) 31,332 (36.2)†
Married 3,215 (53.9) 278,436 (44.1) 898 (40.0) 25,741 (29.7)
Divorced/Separated/Widowed 318 (5.3) 91,304 (14.4) 319 (14.2) 19,462 (22.5)
Education*
≤High School 4,596 (77.1) 494,116 (78.2) 1,514 (67.4) 62,434 (72.1)†
>High School 1,285 (21.6) 129,833 (20.5) 700 (31.2) 22,983 (26.5)
Component
Active Duty 3,003 (50.4) 349,351 (55.3) 1,232 (54.9) 48,615 (56.1)
National Guard/Reserve 2,960 (49.6) 282,517 (44.7) 1,013 (45.1) 38,025 (43.9)
Rank‡
Enlisted 5,638 (94.6) 581,543 (92.0)† 2,055 (91.5) 78,397 (90.5)
Officer 254 (4.3) 43,720 (6.9) 169 (7.5) 7,726 (8.9)
Branch of Service‡
Army 4,088 (68.6) 399,110 (63.2)† 1,443 (64.3) 55,392 (63.9)†
Air Force 585 (9.8) 63,726 (10.1) 452 (20.1) 14,325 (16.5)
Navy 552 (9.3) 74,282 (11.8) 301 (13.4) 13,408 (15.5)
Marine Corps 733 (12.3) 94,183 (14.9) 47 (2.1) 3,469 (4.0)
49
MOHANTY et al. FMS care in Iraq/Afghanistan Veterans
male (n = 733 [15%]) and female (n = 516 [29%]) Veter-
ans had ≥1 follow-up rheumatology specialty care visit.
For the 4,441 male and 1,526 female Veterans who 
had ≥1 primary care visit during the 12 mo following 
their index FMS diagnosis date, the median (range) of 
primary care encounters for male and female Veterans 
was 4 (1–54) and 4 (1–61) visits, respectively. The 
median (range) of mental health encounters for male and 
female Veterans was 5 (0–231) and 6 (0–183) visits, 
respectively. For rheumatology care encounters 12 mo 
following index FMS diagnosis date, the median (range) 
for male and female Veterans was 0 (0–13) and 0 (0–15) 
visits, respectively. Most Veterans (~80%) received a 
combination of primary care and mental health or a com-
bination of primary care and rheumatology care (Table 
3). A higher proportion of female (n = 357 [23%]) than 
male (n = 531 [12%]) Veterans received a combination of 
care from all three settings.
Associations of Combined Primary Care with Mental 
Health and/or Rheumatology Utilization and Pain-
Related Medication Prescriptions
There were 1,830 (41%) males and 589 (39%) females 
who received ≥1 opioid prescription among Veterans with 
≥1 primary care visit during the 12 mo following their 
index FMS diagnosis date. Most Veterans received 
Table 1.
Sociodemographic and military service characteristics among Veterans, returned from Iraq and Afghanistan, who accessed Veterans Health 
Administration (VHA) care during fiscal years 2002–2012. Data presented as n (%).
*Some values are “missing” or “unknown” for these characteristics.
†Some values for these characteristics are “other.”
‡Chi-square test, comparison across FMS status (p < 0.01).
FMS = fibromyalgia syndrome.
Male Veterans (n = 5,692) Female Veterans (n = 2,150)
Top 10 Primary Stop Codes n (%) Top 10 Primary Stop Codes n (%)
Primary Care: 342, 348, 350, or 323
(excluding secondary stop code 135)
1,367 (24.0) Primary Care: 342, 348, 350, or 323
(excluding secondary stop code 135)
632 (29.4)
Chiropractic Care: 436 904 (15.9) Rheumatology/Arthritis: 314 300 (14.0)
Physical Medicine & Rehabilitation: 201 829 (14.6) Physical Medicine & Rehabilitation: 201 283 (13.2)
Pain Clinic: 420 595 (10.5) Women’s Health Clinic: 322, 339, 404, 426, 525, or 
704
173 (8.0)
Rheumatology/Arthritis: 314 461 (8.1) Chiropractic Care: 436 155 (7.2)
Polytrauma/Traumatic Brain Injury/Speech
Pathology: 197 or 219
315 (5.5) Pain Clinic: 420 131 (6.1)
Physical Therapy: 205 281 (4.9) Polytrauma/Traumatic Brain Injury/Speech
Pathology: 197 or 219
69 (3.2)
Complementary Alternative Medicine: 159 118 (2.1) Physical Therapy: 205 63 (2.9)
Laboratory: 108 79 (1.4) Mental Health: 502–524, 527–599, or 725–731 35 (1.6)
Neurology: 106, 126–128, 293, 315, 325, 335, 345, or 
346
76 (1.3) Neurology: 106, 126–128, 293, 315, 325, 335, 345, or 
346
31 (1.4)
Other Outpatient Setting 462 (8.1) Other Outpatient Setting 166 (7.7)
Care Setting
Male Veterans
(n = 4,441)
Female Veterans
(n = 1,526)
Primary Care Only (n) 1,055 (23.8) 288 (18.9)
<4 Visits (%), reference category 695 (15.6) 173 (11.3)
4 Visits (%) 360 (8.1) 115 (7.5)
Primary Care & Mental Health, No Rheumatology (n) 2,706 (60.9) 787 (51.6)
<4 Primary Care Visits (%) 1,135 (25.6) 336 (22.0)
4 Primary Care Visits (%) 1,571 (35.4) 451 (30.0)
Primary Care & Rheumatology, No Mental Health (n) 149 (3.4) 94 (6.2)
<4 Primary Care Visits (%) 88 (2.0) 52 (3.4)
4 Primary Care Visits (%) 61 (1.4) 42 (2.8)
Combined Primary Care, Mental Health, & Rheumatology (n) 531 (12.0) 357 (23.4)
<4 Primary Care Visits (%) 186 (4.2) 124 (8.1)
4 Primary Care Visits (%) 345 (7.8) 233 (15.3)
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≥1 nonopioid pain-related prescription: 3,017 (68%) males 
and 1,124 (74%) females. The median (range) of opioid 
prescriptions for male and female Veterans was 3 (1–42) 
and 2 (1–26), respectively. The median (range) of nonopi-
oid pain-related prescriptions for male and female Veter-
ans was 2 (1–20) and 2 (1–21), respectively.
Contrary to our primary hypothesis, we found that 
compared with <4 primary care visits (i.e., less than regu-
lar primary care), combined regular primary care, mental 
health, and rheumatology utilization was associated with 
2 opioid prescriptions: RRs and 95 percent CIs for male 
and female Veterans were 2.22 (1.13–4.39) and 2.79 
(0.42–18.62), respectively, for the fully adjusted model 
(Model 2, Tables 4–5).
Supporting our secondary hypothesis, we did find 
evidence that compared with Veterans who received less 
Table 2.
Top 10 fibromyalgia syndrome (FMS) outpatient care settings corresponding to index FMS diagnosis, restricted to Veterans who only had one 
unique stop code.*
*13 males and 2 females were missing stop code associated with FMS index date/diagnosis; 258 males and 93 females had ≥2 unique stop code combinations asso-
ciated with FMS index date/diagnosis.
Table 3.
Primary care, mental health, and rheumatology utilization 12 mo after index fibromyalgia syndrome date among Veterans who had at ≥1 primary 
care follow-up visit.* 
*1,108 males and 459 females had <12 mo of follow-up, and 414 males and 260 females had no primary care visits; multiple visits can occur on same day only if 
visits are in different settings.
Model Variable
<4 PC
Visits Only
4 PC
Visits Only
4 PC
Visits & MH
4 PC
Visits & RH
4 PC Visits,
MH & RH
No. at Risk 695 360 1,571 61 345
No. with 2 Opioid Rx 75 78 662 9 151
RR (95% CI)
Unadjusted 1.0 (reference) 2.01 (1.50–2.68) 3.90 (3.13–4.87) 1.37 (0.72–2.59) 4.06 (3.17–5.18)
Model 1* 1.0 (reference) 1.40 (0.71–2.75) 1.77 (1.06–2.98) 0.97 (0.26–3.58) 1.82 (1.07–3.09)
Model 2† 1.0 (reference) 2.02 (0.89–4.57) 2.20 (1.13–4.29) 1.04 (0.17–6.45) 2.22 (1.13–4.39)
No. with 2 Nonopioid Rx 59 67 1,001 20 245
RR (95% CI)
Unadjusted 1.0 (reference) 2.19 (1.58–3.04) 7.51 (5.86–9.61) 3.86 (2.50–5.96) 8.37 (6.49–10.78)
Model 1* 1.0 (reference) 2.60 (1.14–5.91) 4.50 (2.21–9.15) 2.37 (0.71–7.89) 4.92 (2.41–10.05)
Model 2† 1.0 (reference) 3.42 (0.98–11.88) 6.99 (2.32–21.09) 2.02 (0.27–15.11) 7.79 (2.57–23.57)
Model Variable
<4 PC
Visits Only
4 PC
Visits Only
4 PC
Visits & MH
4 PC
Visits & RH
4 PC Visits,
MH & RH
No. at Risk 173 115 451 42 233
No. with 2 Opioid Rx 14 21 155 10 78
RR (95% CI)
Unadjusted 1.0 (reference) 2.26 (1.20–4.25) 4.25 (2.53–7.13) 2.94 (1.41–6.16) 4.14 (2.43–7.06)
Model 1* 1.0 (reference) 2.59 (0.28–23.57) 3.95 (0.61–25.67) —‡ 3.89 (0.60–25.50)
Model 2† 1.0 (reference) 2.12 (0.24–18.55) 2.95 (0.45–19.30) —‡ 2.79 (0.42–18.62)
No. with 2 Nonopioid Rx 24 27 300 16 169
RR (95% CI)
Unadjusted 1.0 (reference) 1.69 (1.03–2.78) 4.79 (3.29–6.99) 2.75 (1.61–4.69) 5.23 (3.58–7.64)
Model 1* 1.0 (reference) 1.65 (0.44–6.14) 3.15 (1.14–8.77) 1.91 (0.50–7.36) 3.38 (1.22–9.41)
Model 2† 1.0 (reference) 1.03 (0.26–4.12) 2.19 (0.82–5.87) 0.85 (0.21–3.45) 2.32 (0.87–6.21)
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than regular primary care (<4 primary care visits in the 12 
mo after index FMS date), combined regular primary 
care, mental health, and rheumatology utilization was 
associated with 2 nonopioid pain-related prescriptions: 
RRs and 95 percent CIs for male and female Veterans 
were 7.79 (2.57–23.57) and 2.32 (0.87–6.21), respec-
tively, for the fully adjusted model (Model 2, Tables 4–5).
These results were not materially altered when we 
further adjusted for the year of index FMS diagnosis and 
whether the index diagnosis was in a rheumatology setting 
(Appendix 2, available online only). Also, our results 
were robust to recoding of individuals with one diagnosis 
of anxiety, PTSD, or depression to having no diagnosis 
for these conditions.
Table 4.
Associations of combined regular primary care and mental health and/or rheumatology utilization and pain-related medication prescriptions 
(opioid or nonopioid) 12 mo following index fibromyalgia syndrome (FMS) diagnosis date among male Veterans (n = 4,441).
*Model 1 is adjusted for no. anxiety diagnoses (1, 2, 3), no. posttraumatic stress disorder diagnoses (1, 2, 3), no. depression diagnoses (1, 2, 3), and Charlson 
Comorbidity Index (1, 2); each value is included as an indicator variable.
†Model 2 adjusts for same variables in Model 1 in addition to sociodemographic variables: age at FMS index date (2 indicator variables: >30–40, >40), white non-
Hispanic race/ethnicity, married marital status, greater than high school education, and military characteristics: Active Duty, branch of service (4 indicator variables: 
Air Force, Navy, Marine Corps, Coast Guard).
CI = confidence interval, MH = mental health, No. = number, PC = primary care, RH = rheumatology, RR = risk ratio, Rx = prescription.
Table 5.
Associations of combined primary care and mental health and/or rheumatology utilization and pain-related medication prescriptions (opioid or 
nonopioid) 12 mo following index fibromyalgia syndrome (FMS) diagnosis date among female Veterans (n = 1,526).
*Model 1 is adjusted for no. anxiety diagnoses (1, 2, 3), no. posttraumatic stress disorder diagnoses (1, 2, 3), no. depression diagnoses (1, 2, 3), and Charlson 
Comorbidity Index (1, 2); each value is included as an indicator variable.
†Model 2 adjusts for same variables in Model 1 in addition to sociodemographic variables: age at FMS index date (2 indicator variables: >30–40, >40), white non-
Hispanic race/ethnicity, married marital status, greater than high school education, and military characteristics: Active Duty, branch of service (4 indicator variables: 
Air Force, Navy, Marine Corps, Coast Guard).
‡Too few events limited risk estimation.
CI = confidence interval, MH = mental health, No. = number, PC = primary care, RH = rheumatology, RR = risk ratio, Rx = prescription.
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DISCUSSION
To the best of our knowledge, this is the first study to 
report the prevalence and related sociodemographic and 
military characteristics of FMS among national OIF/OEF/
OND Veterans. We report a 10 yr FMS prevalence of 
0.9 percent among males and 2.4 percent among females 
who accessed the VHA. Over a quarter of FMS diagnoses 
were documented in a primary care setting. Compared 
with Veterans without FMS, Veterans with FMS were 
more likely to be female, older, never/currently married, 
and to have served in the Army (males) or Air Force 
(females). One year following index FMS diagnosis, most 
Veterans sought a combination of primary care and mental 
health and/or rheumatology. Contrary to our primary 
hypothesis, Veterans with FMS with regular primary care 
visits combined with mental health and rheumatology vis-
its were more likely to be prescribed 2 opioids during 
the 12 mo following index FMS diagnosis. Combined 
care was also associated with 2 nonopioid pain-related 
prescriptions.
The prevalence of FMS in our study of OIF/OEF/OND 
Veterans was within the range reported in studies of civil-
ian [1] and military populations [3]. Researchers have 
reported that among Gulf war Veterans, deployment (ver-
sus nondeployment) may be associated with a doubling of 
the risk of FMS (odds ratio 2.32 [95% CI: 1.02–5.27]) 
[29]. The present study did not examine the association 
between deployment and FMS diagnosis. Other character-
istics that we found to be related to FMS diagnoses were 
consistent with prior studies, including older age and 
female sex [1,3,5,14]. The FMS-female sex association is 
worth noting because women continue to be one of the 
fastest growing subsets of VHA users [30]. We are 
unaware of prior studies that report a higher prevalence of 
FMS among those of Hispanic ethnicity, though there are 
limited investigations of race/ethnicity and FMS. Studies 
of chronic pain in general support that Hispanic and Afri-
can American race/ethnicities are at greater risk of experi-
encing pain, but it is unclear that these differences remain 
after controlling for other confounding variables [31]. If 
our findings are replicated, they may provide evidence for 
potential disparities in the experience of FMS and FMS 
management among ethnic minorities. Identification of 
disparities in pain and pain management has been high-
lighted as an area of needed future research in the Institute 
of Medicine’s “Relieving Pain in America: A Blueprint for 
Transforming Prevention, Care, Education and Research” 
[32].
Consistent with a prior non-VHA study of FMS, 
FMS diagnoses were most common in primary care [15]. 
In our study of the VHA, other predominant nonrheuma-
tology clinical settings of FMS diagnoses included chiro-
practic care, physical medicine and rehabilitation, and 
pain clinics. Also, among females, women’s health-
related clinics were one of the top five settings of FMS 
diagnoses. Since most diagnoses of FMS occur outside 
the rheumatology setting, it may be important to ensure 
that clinicians in these settings are made aware of and 
trained in the latest evidence-based practice guidelines 
for diagnosing and managing FMS and that procedures 
are in place for timely referrals to rheumatology, espe-
cially if a diagnosis is elusive [10]. Some experts recom-
mend that rheumatologists train primary care colleagues 
on the recognition of FMS [33].
Investigators have demonstrated that patients with 
FMS in both civilian and military populations have 
higher utilization of healthcare. Berger et al. reported that 
compared with civilians without FMS, those with FMS 
had twice as many outpatient and four times as many 
emergency room visits over 12 mo [14]. Other investiga-
tors have reported that utilization of healthcare is higher 
for FMS than other chronic medically unexplained symp-
toms among military personnel, including irritable bowel 
syndrome and chronic fatigue syndrome [3]. Therefore, it 
may not be surprising that in the present study most Vet-
erans sought a combination of primary care and mental 
health and/or rheumatology specialty care 12 mo follow-
ing their index FMS diagnosis; this was especially evi-
dent for combined primary care with mental health.
Whether utilization of combined care in our study is 
a reflection of a guideline-recommended, interdisciplin-
ary, team-based approach; comorbid diagnoses; and/or 
challenges related to identifying and managing FMS is 
uncertain. On the one hand, FMS is known to be associ-
ated with a number of comorbid conditions; seven condi-
tions were reported by investigators of a civilian 
population-based study, including depression, anxiety, 
headache, irritable bowel syndrome, chronic fatigue syn-
drome, systemic lupus erythematous, and rheumatoid 
arthritis [5]. Each of these conditions was 2 to 7 times 
more likely to be present in patients with FMS than 
patients without FMS. PTSD is another condition that is 
often comorbid with FMS and highly prevalent in the 
OIF/OEF/OND Veteran population [11,34–37]. While we 
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did not examine all reported comorbid conditions of 
FMS, we did examine mental health-related conditions. 
The prevalence of ≥1 diagnosis for anxiety, PTSD, and 
depression 12 mo following index FMS date was 21.5, 
51.0, and 21.0 percent, respectively. Restricting to indi-
viduals with ≥2 diagnoses reduced these prevalence esti-
mates by 5 percent. The combined utilization of primary 
care with mental health among Veterans in our study may 
be expected given the high prevalence of mental health 
conditions. On the other hand, combined care may be a 
reflection of high healthcare utilization overall, which 
may indicate complexity of the patients, poor coordina-
tion of care, and challenges related to diagnosing FMS 
[7,10,38]. We did not examine overall healthcare utiliza-
tion of Veterans seeking combined care (vs those with 
primary care visits only), nor could we examine the rea-
sons for follow-up utilization. As a result, it is unclear 
whether combined utilization represents recommended 
interdisciplinary, team-based approaches for managing 
FMS; higher utilization of services to independently 
address the multiple comorbid conditions [11]; or per-
haps overutilization of VHA care. Lastly we note that 
stop codes, for mental health services in particular, likely 
reflect various levels of interdisciplinary and integrative 
treatment, which the current study could not examine.
We sought empiric evidence to support the clinical 
practice guideline recommendations that combined care 
is associated with best practices, i.e., less opioid use and 
more use of nonopioid pain-related medication. Contrary 
to our first hypothesis, results support associations of 
combined care with a higher risk of receiving 2 opioid 
prescriptions. We note that this finding is correlational, 
and we are unable to infer a direction of causality. Bear-
ing this in mind, there are several potential explanations 
for our findings. The association between indicators of 
combined care and opioid therapy is consistent with clin-
ical practice guidelines for opioid therapy [28]. Also, it 
may be that patients who receive opioid therapy are those 
with more complex, severe, and treatment-refractory 
conditions. Thus, the evidence for an association between 
combined care and opioid therapy may be consistent with 
a prior escalation of care in the service of attempting to 
better manage pain.
Our study robustly supports the hypothesis that Vet-
erans with utilization of mental health and rheumatology 
in addition to regular primary care are more likely to be 
prescribed 2 nonopioid pain-related medications (guide-
line-adherent practice). For instance, when we explored a 
change in our reference category to “only regular primary 
care” users (rather than less than “only regular primary 
care” users), associations between combined regular pri-
mary care, mental health, and rheumatology utilization 
and 2 nonopioid pain-related medications remained sta-
tistically significant (Appendix 2, Model 2). In contrast, 
there is less evidence supporting that Veterans with com-
bined care are more likely to be prescribed opioids (not 
consistent with guideline recommendations). When we 
explored a change in our reference category to “only reg-
ular primary care” users, the association of combined 
care and opioid use was no longer statistically significant. 
Thus, it may be that regular or greater primary care utili-
zation (compared with less than regular primary care uti-
lization) and not combined care per se is associated with 
higher likelihood of being prescribed opioids, perhaps 
due to other indications for opioid prescription and the 
necessary, regular encounters to responsibly manage the 
opioid use.
LIMITATIONS
As with all studies that rely on administrative data, 
there is the potential for misclassification of FMS. Since 
we were interested in focusing our analyses on Veterans 
with true diagnoses of FMS, we required that Veterans 
have ≥2 ICD-9-CM diagnoses of FMS in a 12 mo period 
or ≥1 diagnosis in a rheumatology specialty care setting. 
Although this definition has not been examined for valid-
ity in the OIF/OEF/OND Veteran population, similar def-
initions have been used in studies of military personnel 
and our prevalence estimates in male and female Veter-
ans are similar to those reported previously [3]. Another 
weakness was that we were unable to determine the inci-
dent date of FMS diagnosis, which precluded analyses of 
causal relationships and limited our interpretation of tem-
poral relationships. We relied on an index FMS diagnosis 
date, the first documentation of FMS in VHA diagnosis 
codes over the study period.
Interpretation of the results related to the examina-
tion of healthcare utilization and treatment during the 
12 mo following the index FMS date should be made in 
the context of several potential limitations. These include 
use of combined utilization of regular primary care with 
mental health and/or rheumatology care as a proxy for an 
interdisciplinary, team-based approach to FMS care. We 
are uncertain whether this proxy is appropriate or 
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whether it is a reflection of escalated care utilization 
driven by patient need that is not interdisciplinary or inte-
grative in nature. Since we did not examine reasons 
(including diagnoses) related to follow-up primary care, 
mental health, and rheumatology visits, we cannot make 
strong assertions regarding the potential benefit or harm 
of combined care for FMS. Second, we did not account 
for the potential variability in the specific knowledge or 
clinical expertise of the providers, which may be a valu-
able area for future research. Third, since we were unable 
to identify an explicit definition of regular primary care 
for FMS in the current “VA/DOD Clinical Practice 
Guideline for the Management of Chronic Multisymptom 
Illness” [17], we used the median number of visits in 
12 mo, 4 primary care visits, to define “regular primary 
care,” which may not be clinically relevant or may have 
limited generalizability. We note that our definition of 
“regular primary care” as 4 primary care visits/yr is 
consistent with some previous studies of management of 
somatoform disorders [39]. Fourth, although we 
attempted to control for potential confounding variables, 
there may be residual confounding, which if present 
would bias our estimates of risk. To ensure that we had 
adequate power to estimate RRs, we used the medians 
(among Veterans with medication use) for analyses of 
pain-related medication associations. However, espe-
cially for the analyses of opioids, a more clinically rele-
vant outcome may be chronic use. Because we did not 
have details on dose or longitudinal duration of continued 
or intermittent treatment, we were unable to examine 
chronic use. Also, we used prescription history as noted 
in the electronic medical record as an indicator for medi-
cation use; we did not determine whether patients actu-
ally consumed their medications or how adherent they 
were to prescription instructions. We were unable to 
examine the clinical indication for the medication pre-
scriptions. For example, some of the nonopioid pain-
related medications, antidepressants and gabapentinoids, 
in particular, may have been prescribed for the manage-
ment of nonpain medical and mental health comorbidities 
that are common among patients with FMS. There may 
have been losses to follow-up, which could introduce 
selection bias, although we attempted to address this by 
including only Veterans with ≥1 primary care visit 
through the VHA during the 12 mo following FMS index 
date. Future investigations are needed to examine other 
guideline-recommended treatments for FMS, including 
patient education, graded exercise, cognitive behavioral 
therapy, and complementary and alternative medicine 
therapies.
CONCLUSIONS
Our present study extends the current scope of 
research on FMS to include OIF/OEF/OND Veterans 
who access VHA. Our study confirmed several previ-
ously identified risk factors for FMS and identified 
potential new risk factors (e.g., Hispanic ethnicity) that 
warrant further investigation. Contrary to our hypothesis, 
Veterans with FMS who utilized regular primary care, 
mental health, and rheumatology (combined care) were 
more likely to be prescribed opioids. However, closer 
examination suggests that regular primary care (relative 
to less than regular primary care) is driving the associa-
tion. Combined care was also associated with 2 nonopi-
oid pain-related prescriptions; unlike the findings for 
opioid medications, results were not materially altered in 
our sensitivity and exploratory analyses. Future studies 
are needed to more closely examine associations of inter-
disciplinary, team-based approaches to FMS care, overall 
VHA utilization, and recommendations for FMS treat-
ment. Such studies can support the implementation of 
evidence-based management of FMS in VHA.
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